Safety of efavirenz in first-trimester of pregnancy: A systematic review and meta-analysis of outcomes from observational cohorts

AIDS

Volumn 24, Issue 10, 2010, Pages 1461-1470

  Ford, Nathan ^a   Mofenson, Lynne ^b   Kranzer, Katharina ^c   Medu, Lanre ^d   Frigati, Lisa ^e   Mills, Edward J ^f   Calmy, Alexandra ^g  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d SIMON FRASER UNIVERSITY   (Canada)

^e RED CROSS WAR MEMORIAL CHILDREN S HOSPITAL   (South Africa)

^f UNIVERSITY OF OTTAWA   (Canada)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

birth defects; congenital abnormalities; efavirenz; HIV AIDS; pregnancy

Indexed keywords

EFAVIRENZ;

ABORTION; ARTICLE; BIRTH DEFECT; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENINGOMYELOCELE; META ANALYSIS; NEURAL TUBE DEFECT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREGNANCY TERMINATION; PREMATURE LABOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; STILLBIRTH; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ABNORMALITIES, DRUG-INDUCED; ANTI-HIV AGENTS; BENZOXAZINES; FEMALE; HIV INFECTIONS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; RISK FACTORS;

EID: 77953914155     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833a2a14     Document Type: Article

References (45)

1. Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16:299-300.
2. De Santis M, Carducci B, De Santis L, Cavaliere A, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002; 162:355.
3. Lewis-Hall FC. Important Change in SUSTIVA (efavirenz) Package Insert-Change from Category C to D. Bristol-Myers Squibb Company 2005. http://www.fda.gov. [Accessed 31 December 2009]
4. Antiretroviral Pregnancy Registry Steering Committee. Antire-troviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2009. Wilmington, NC: Registry Coordinating Center 2009. www.APRegistry.com. [Accessed 31 December 2009]
5. Townsend C, Willey B, Cortina-Borja M, Peckham C, Tookey P. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS 2009; 23:519-524.
6. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents-November 2009. World Health Organization, Geneva, Switzerland, 2009. http://www.who.int/hiv/pub/arv/rapid-advice-art.pdf. [Accessed 31 December 2009]
7. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, April 29 2009; 1-90. http://aidsinfo.nih.gov/Content Files/PerinatalGL.pdf. [Accessed 31 December 2009]
8. European AIDS Clinical Society. Guidelines: Clinical management and treatment of HIV infected adults in Europe. Version 5. Paris, November 2009. http://www.europeanaidsclinicalsocie-ty.org/guidelinespdf/1-Treatment-of-HIV- Infected-Adults.pdf. [Accessed 31 December 2009]
9. Baroncelli S, Tamburrini E, Ravizza M, Dalzero S, Tibaldi C, Ferrazzi E, et al. Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS 2009; 23:513-520.
10. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2009; 334:307-320.
11. Bera E, McCausland K, Nonkwelo R, Mgudlwa B, Chacko S, Majeke B. Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital. AIDS 2010; 24:283-289.
12. Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, Maartens G. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 2008; 22:2117-2125.
13. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, et al. Outcomes of nevirapine-and efavirenz-based antiretroviral therapy when coadministered with rifam-picin-based antitubercular therapy. JAMA 2008; 300:530-539.
14. Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-926. (Pubitemid 351632017)
15. Meade MO, Guyatt GH, Cook RJ, Groll R, Kachura JR, Wigg M, et al. Agreement between alternative classifications of acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 163:490-493. (Pubitemid 32158534)
16. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2:121-145.
17. Sheehe P. Combination of log relative risk in retrospective studies of disease. Am J Pub Health 1966; 56:1745-1750.
18. Joao EC, Calvet GA, Krauss MR, Freimanis Hance L, Ortiz J, Ivalo SA, et al. NISDI Perinatal Study Group. Maternal anti-retroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study. J Acquir Immune Defic Syndr 2010; 53:176-185
19. Fernandez Ibieta M, Ramos Amador J, Bellon Cano J, González- Tomé M, Guillén Mart́in S, Navarro Gómez M, et al. Malformaciones congenitas en una cohorte de ninos no infectados, hijos de madres infectadas por el virus de la inmunodeficiencia humana. An Pediatr(Barc) 2009; 70:253-264.
20. Saitoh A, Hull AD, Franklin P, Spector SA. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 2005; 25:555-556.
21. Watts DH, Li D, Handelsman E, Tilson H, Paul M, Foca M, et al. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 2007; 44:299-305.
22. Conway J, Scott G, Muenz D, Brogly S, Knapp K, Talbot J, et al. Prevalence of Congenital Anomalies in Infants with in Utero Exposure to Antiretrovirals: IMPAACT P1025. 17th Conference on Retroviruses and Opportunistic Infections, San Franciso, 2010. Abstract 923.
23. Bussmann H, Wester CW, Wester CN, Lekoko B, Okezie O, Thomas AM, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J Acquir Immune Defic Syndr 2007; 45:269-277.
24. Coffie P, Moh R, Tonwe-Gold B, Amani-Bosse C, Messou E, Gabillard D, et al. Issues des grossesses chez des femmes exposées à l'efavirenz à Abidjan, Côte d'Ivoire. 5ème Confér-ence Francophone sur le VIH/Sida, Casablanca, Morocco, 28-31 March 2010: Abstract no. 448/73P
25. Patel D, Thorne C, Fiore S, Newell ML, European Collaborative Study. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women. J Acquir Immune Defic Syndr 2005; 40:116-118.
26. Machado ES, Hofer CB, Costa TT, Nogueira SA, Oliveira RH, Abreu TF, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect 2009; 85:82-87.
27. Gonzalez-Tome M, Fernandez-Ibieta M, Ramos Amador J, MuñozGalligo E, Rojo C, Nieto O, et al. The Spanish cohort of HIV-infected mother-infant pairs. Efavirenz in pregnancy: maternal characteristics of women who become pregnant on EFV-containing regimen and neonatal effects. XVII International AIDS Conference, 3-8 August 2008, Mexico City, Mexico: Abstract no. CDB0207.
28. Floridia M, Tamburrini E, Ravizza M, Tibaldi C, Bucceri A, Maccabruni A, et al. Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs. Antivir Ther 2006; 11:941-946.
29. Westreich D, Robel D, MacDonald P, Majuba P, Maskew M, Nagar S, Jaffray I, MacPhail Abstract P, Cole S, Sanne I. Pregnancy, Efavirenz, and Birth Outcomes in Johannesburg. 17th Conference on Retroviruses and Opportunistic Infections, San Franciso, 2010. Abstract 922.
30. Laher F, Forrest J, Mohapi L, Gray G. Efavirenz Conceptions in Soweto, South Africa. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa: Abstract TUPEC047.
31. Rossouw T. Quantifying antiretroviral risk in pregnancy. S Afr Med J 2007; 97:1016-1016
32. Joao E, Calvet G, Cunha C, Menezes J, Martins E, Medeiros A, et al. Pregnancy outcome in women exposed to efavirenz. XVI International AIDS Conference, 13-18 August 2006, Toronto, Canada: Abstract no. CDB0698.
33. Batallan A, Moreau G, Levine M, Longuet P, Bodard M, Legac S, et al. In utero exposure to efavirenz: evaluation in children born alive. 2nd IAS Conference on HIV Pathogenesis and Treatment, 13-16 July 2003, Paris, France: Abstract no. 1100.
34. Jeantils V, Khuong MA, Delassus JL, Honoré P, Taverne B, Uzan M, Tassi S. [Efavirenz (Sustiva) in pregnancy: a study about 12 HIV patients]. Gynecol Obstet Fertil 2006; 34:593-596.
35. Joao E, Calvet G, Sidi L, Cruz L, Cardoso C, Cunha C, et al. Increased incidence of spontaneous abortion during first trimester exposure to efavirenz. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney, Australia: Abstract TUPEB113.
36. Shepard TH. Catalog of teratogenic agents. 6th ed. Baltimore: Johns Hopkins University Press; 1989.
37. Correa A, Cragan J, Kucik J, Alverson C, Gilboa S, Balakrishnan R, et al. Metropolitan Atlanta Congenital Defects Program 40th Anniversary Edition Surveillance Report: Reporting Birth Defects Surveillance Data 1968-2003. Birth Defects Research (Part A) Clin Mol Teratol 2007; 79:65-93.
38. Goujard J, de Vigan C, Vodovar V, Verite V, Dehe S. Douze années d'enrégistrement des malformations congénitales à Paris (1985-1996). Med Foetale 1999; 39:20-28.
39. Human Genetics Policy Guidelines for the Management and Prevention of Genetic Disorders, Birth Defects and Disabilities. Pretoria, South Africa: Sub-Directorate, Human Genetics, National Department of Health 2008. www.doh.gov.za. [Accessed 31 December 2009]
40. Rankin J, Pattenden S, Abramsky L, Boyd P, Jordan H, Stone D, et al. Prevalence of congenital anomalies in five British regions, 1991-1999. Arch Dis Child Fetal NeonatolEd2005; 90:F374-F379.
41. Venter PA, Christianson AL, Hutamo CM, Makhura MP, Gericke GS. Congenital anomalies in rural black South African neo-nates: a silent epidemic? S Afr Med J 1995; 85:15-20.
42. Chersich MF, Urban MF, Venter FW, et al. Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther 2006; 7:11.
43. ART-LINC Collaboration of International Databases to Evaluate AIDS (IeDEA), KeiserO,Anastos K,etal.Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008; 13:870-879
44. UK MRC Vitamin Study Research Group. Lancet 1991; 338: 131-137.
45. Abbott Laboratories. Depakene drug label. April 23, 2009. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/018081s047, 018082s032lbl.pdf. [Accessed 31 December, 2009]